Health

Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026

Servier presented updated four-year results from the Phase 2 FIREFLY-1 study of OJEMDA (tovorafenib) in relapsed/refractory pediatric low-grade glioma at the Society for Neuro-Oncology Annual Meeting in Philadelphia on Nov. 14. According to data presented by investigator Dr. Daniel Landi, the treatment demonstrated a median time to next treatment of 50.9 months among 76 efficacy-evaluable patients.

The updated analysis showed that among 41 patients who entered an optional post-treatment observation period after completing 26 cycles of therapy, 76% (n=31) remained free of subsequent treatment for at least 12 months, and 54% (n=22) remained treatment-free for at least 24 months, according to the data. The median treatment-free interval had not been reached at the time of the data cutoff.

Of the 76 efficacy-evaluable patients, 54% (n=22) experienced tumor rebound after stopping treatment, and seven of those patients were retreated, the study showed.

Overall, 27% of patients (n=11) were retreated with OJEMDA. At their last scan, nine of those patients had a smaller tumor than prior to retreatment, according to the presentation.

Among a subgroup of 13 patients with BRAF V600E mutations, five experienced tumor rebound and four were retreated, the data showed.

The four-year analysis had a median study duration of 52.5 months in the registrational arm as of the June 5, 2026, data cutoff, according to the presentation. Patients received OJEMDA orally once weekly in 28-day cycles for 26 cycles, after which they could continue treatment or enter the observation period.

The safety profile remained consistent with the established profile, officials said. In the safety analysis set of 137 patients, the most common Grade 3 or higher treatment-related adverse events observed in at least 5% of patients included reduced growth velocity (36%), anemia (14%), increased CPK (11%), maculopapular rash (8%), and increased ALT (5%), according to the data.

There were no treatment-related deaths and no additional discontinuations due to treatment-related adverse events since the three-year data cutoff, the study showed. In a growth analysis set of 90 patients, 88% (n=79) demonstrated growth recovery, irrespective of the degree of on-treatment growth suppression, according to the presentation.

“With four years of follow-up from FIREFLY-1, we are building a more complete picture of OJEMDA’s long-term outcomes, which will help physicians and families make critical treatment decisions,” Elly Barry, MD, vice president of clinical development at Servier Pharmaceuticals, said in a statement.

Daniel Landi, MD, of Duke University and Duke Cancer Institute, an investigator on the trial, presented the findings. “For children and families living with pediatric low-grade glioma, time spent off treatment is meaningful,” Landi said in the statement.

The study included patients aged six months to 25 years with relapsed or refractory BRAF-altered pediatric low-grade glioma (pLGG). The analysis assessed exploratory endpoints of time to next treatment and treatment-free interval.

OJEMDA is a Type II RAF kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. It is indicated for patients 6 months and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The indication is approved under accelerated approval based on response rate and duration of response; continued approval may be contingent upon verification of clinical benefit in confirmatory trials, according to Servier.

pLGG is the most common brain tumor in children, with an estimated U.S. incidence of 1,100 and a European incidence of 700 children per year eligible for front-line systemic therapy. BRAF alterations account for more than 50% of pLGG cases worldwide, according to the company.

.

Evan Vega

Evan Vega is a national affairs correspondent covering politics, public health, and regional policy across multiple states. His reporting connects statehouse developments to their real-world impact on communities. Evan has covered three presidential cycles and specializes in the intersection of state governance and federal policy.